

# Pablo Gajate

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/75024/publications.pdf>

Version: 2024-02-01

36  
papers

933  
citations

840776

11  
h-index

477307

29  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1137  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgery of pancreatic metastasis from renal cell carcinoma. <i>Cirug�a Espa�ola (English Edition)</i> , 2022, 100, 50-52.	0.1	0
2	Successful rapid desensitization to Atezolizumab in delayed hypersensitivity confirmed with Lymphocyte Transformation Test.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	3.8	4
3	Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature. <i>Frontiers in Pharmacology</i> , 2022, 13, 774170.	3.5	15
4	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. <i>Biomedicines</i> , 2022, 10, 537.	3.2	9
5	Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 546-546.	1.6	3
6	Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments. <i>European Journal of Cancer</i> , 2022, 166, 229-239.	2.8	17
7	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60�mg Per Day Compared with the Cabozantinib Capsule at 140�mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 515-524.	4.5	9
8	Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study. <i>European Thyroid Journal</i> , 2022, 11, .	2.4	2
9	Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. <i>Clinical and Translational Oncology</i> , 2021, 23, 882-891.	2.4	5
10	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	3.1	52
11	Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and <i>FGFR3</i> mRNA overexpression in the phase Ib/II FORT-2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4521-4521.	1.6	13
12	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114.	27.0	427
13	Sunitinib and Evofosfamide (<sc>TH</sc>-302) in Systemic Treatment-Na�ve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The <sc>GETNE</sc>-1408 Trial. <i>Oncologist</i> , 2021, 26, 941-949.	3.7	12
14	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	1.6	49
15	Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case Report. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.3	0
16	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti�PD-1 for patients with anti�PD-1 refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	51
17	Cirug�a en las met�stasis pancre�ticas por carcinoma renal. <i>Cirug�a Espa�ola</i> , 2020, 100, 50-50.	0.2	0
18	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). <i>Oncologist</i> , 2020, 25, 745-e1265.	3.7	25

#	ARTICLE	IF	CITATIONS
19	Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and <i>FGFR</i> mRNA overexpression.. Journal of Clinical Oncology, 2020, 38, 5014-5014.	1.6	23
20	Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on <i>FGFR</i> mRNA overexpression.. Journal of Clinical Oncology, 2020, 38, 527-527.	1.6	4
21	Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.. Journal of Clinical Oncology, 2020, 38, 542-542.	1.6	30
22	Practice change in the management of metastatic urothelial carcinoma after ASCO 2020. World Journal of Clinical Oncology, 2020, 11, 976-982.	2.3	1
23	CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.. Journal of Clinical Oncology, 2020, 38, TPS770-TPS770.	1.6	0
24	Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH "Grupo Centro" of Genitourinary Tumors. Kidney Cancer, 2019, 3, 177-182.	0.4	4
25	Real-World Outcome of 173 Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC) Cases: The Experience of the Center Group for Genitourinary Tumors. Kidney Cancer, 2019, 3, 41-50.	0.4	2
26	The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of the combination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).. Journal of Clinical Oncology, 2019, 37, 4105-4105.	1.6	5
27	Interim analysis of ibrutinib plus paclitaxel for patients with metastatic urothelial carcinoma previously treated with platinum-based chemotherapy.. Journal of Clinical Oncology, 2019, 37, 365-365.	1.6	1
28	Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.. Journal of Clinical Oncology, 2019, 37, TPS503-TPS503.	1.6	3
29	Direct impact of clinical research in metastatic renal cell carcinoma (mRCC): A cost-effectiveness analysis of patient care outcomes and cost savings in a real-life scenario of a large public university hospital in Spain.. Journal of Clinical Oncology, 2019, 37, 637-637.	1.6	3
30	Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy.. Journal of Clinical Oncology, 2019, 37, 4522-4522.	1.6	0
31	Prognostic and predictive role of the PI3K/AKT/mTOR pathway in neuroendocrine neoplasms. Clinical and Translational Oncology, 2018, 20, 561-569.	2.4	10
32	Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma. Autopsy and Case Reports, 2018, 8, e2018005.	0.6	3
33	Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treatment Reviews, 2017, 58, 41-50.	7.7	104
34	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. Future Oncology, 2017, 13, 615-624.	2.4	32
35	Emerging use of everolimus in the treatment of neuroendocrine tumors. Cancer Management and Research, 2017, Volume 9, 215-224.	1.9	14
36	How do patterns of progression influence treatment selection after chemohormonal therapy in patients with metastatic hormone sensitive prostate cancer?. Journal of Clinical Oncology, 2017, 35, e16504-e16504.	1.6	1